Abstract
Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the characterisation of the production strain and on the safety for the target species of monensin sodium (Elancoban® G200). The current application is a follow-up of the re-evaluation application of monensin sodium, intended for use as a coccidiostat in chickens for fattening at 100-125 mg monensin sodium/kg complete feed, chickens reared for laying at 100-120 mg monensin sodium/kg complete feed and in turkeys at 60-100 mg monensin sodium/kg complete feed. Based on the new data provided, the FEEDAP Panel confirms that the production strain belongs to a new, not yet described species and will be referred to as Streptomyces sp. NRRL B-67924. Based on the available data, the FEEDAP Panel cannot conclude on the safety of the additive for the chickens for fattening at the currently authorised maximum level (i.e. 125 mg monensin sodium/kg complete feed). However, the Panel considers that monensin sodium from Elancoban® G200 is safe at a maximum concentration of 100 mg/kg complete feed for chickens for fattening. The same conclusion is extended for chickens reared for laying.